UNCY News and Press, Unicycive Therapeutics Inc. From 11/08/22

--News Direct-- Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/ View original content to download multimedia: https://newsdirect.com/news/unicyc...

(NewsDirect) Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/ Copyright (c) 2022 TheNewswire - All rights reserved.

Multiple Data Presentations Support the Company’s Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease Independently Hosted Key Opinion Leader Panel to Highlight Potential of Company’s Product Can...

--News Direct-- You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? In addition to powering healthy cells, mitochondria are also important players in certain diseases. This is especi...

LOS ALTOS, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chairman and Chief Executive Officer of Unicycive, ...

--News Direct-- Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 requ...

Unicycive Therapeutics ( NASDAQ: UNCY ) said treatment with UNI-494 showed a statistically significant reduction of a key biomarker of kidney injury in a preclinical study of an animal model of acute kidney injury (AKI). The company evaluated the effect of UN...

Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA approved drugs for its treatment On track to file regulatory submission by year end 202...

LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Company management will participate at the upcoming H.C. Wainwright 24 ...

LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts to be presented as posters and one publication...